Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.

Scientific microscope with visual representation of DNA helix

Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor

March 16, 2021

Trethera announced the appointment of Frank Baxter, Jefferies Chairman Emeritus and former U.S. Ambassador to Uruguay, as special advisor. He will counsel the board on financing strategies including private equity, public markets, and debt options.

Read More 

Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors



February 24, 2021

Trethera closed a $3.2M seed funding round from existing investors, reinforcing confidence in TRE‑515. The funds will be used for working capital and support ongoing clinical-stage development.

Read More 

Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis



January 7, 2021

Trethera announced FDA Orphan Drug Designation for TRE‑515 in acute disseminated encephalomyelitis (ADEM). This early-stage recognition offers incentives including trial design support, FDA grant eligibility, fee exemptions, and seven years of U.S. exclusivity.

Read More 

Globally Renowned Research Scientist Dr. Michael Shepard Joins Trethera’s Scientific Advisory Board



December 8, 2020

Trethera welcomed Dr. Michael Shepard, a Lasker Prize Laureate and pioneer in HER2-targeted therapy like Herceptin, to its Scientific Advisory Board. Dr. Shepard will advise on TRE‑515’s translational strategy in cancer and autoimmune disease.

Read More 

Trethera Announces U.S. Patent Application Filed for TRE-515, Extending Major Markets Exclusivity until 2041



November 2, 2020

Trethera filed a U.S. provisional patent application for the unique composition of TRE‑515, which, if granted, will provide global market exclusivity through 2041. IP counsel Wilson Sonsini Goodrich & Rosati led the filing strategy.

Read More 